Date:11/4/2010

us Therapeutics Inc.-(4,666)(4,666)Investment income5,241(141)5,100Interest expense(9,421)122(9,299)Gain on investments2,794(3)2,791Loss from continuing operations, before income tax expense (17,251)1,188(16,063)Income tax expense(873)-(873)Net loss from continuing operations(18,124)1,188(16,936)Discontinued operations:Loss from discontinued operations(29)-(29)Gain on sale of Ibis Biosciences, Inc., net of tax187,153-187,153Net income from discontinued operations, net of tax187,124-187,124Net income169,0001,188170,188Net loss attributable to noncontrolling interest in Regulus Therapeutics Inc.2,906(2,906)-Net income attributable to Isis Pharmaceuticals, Inc. common stockholders$171,906$(1,718)$170,188Basic and diluted net income (loss) per share:Net loss from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders$(0.16)$(0.17)Net income from discontinued operations1.911.91Basic and diluted net income$1.75$1.74Shares used in computing basic and diluted net income (loss) per share97,98897,988(1)  Assuming Isis would have adopted the new accounting standard retrospectively, these are the adjustments that would have been made to Isis' 2009 Statement of Operations.Isis Pharmaceuticals, Inc.Reconciliation of GAAP to Pro Forma Basis:  Condensed Consolidated Operating Expenses and Income (Loss) From Operations(In Thousands)Three months ended,

September 30,Nine months ended,

September 30, 2010200920102009(unaudited)(unaudited)As reported operating expenses according to GAAP$37,571$37,167$114,551$105,204Excluding compensation expense related to stock options(2,960)(3,546)(9,448)(9,814)Pro forma operating expenses$34,611$33,621$105,103$95,390As reported loss from operations according to GAAP$(8,947)$(10,396)$(32,498)$(15,865)Excluding compensation expense related to stock options(2,960)(3,546)(9,448)(9,814)Pro forma loss from operations$(5,987)$(6,850)$(23,050)$(6,
'/>"/>

SOURCE Isis Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results